Cyclophosphamide
Payments companies reported to CMS as associated with Cyclophosphamide. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Cyclophosphamide, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Cyclophosphamide
These are the largest totals companies reported as associated with Cyclophosphamide. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Mohit Narang | Owing Mills, MD | Medical Oncology | $5,000.00 |
| Vikram Gorantla | Pittsburgh, PA | Hematology & Oncology | $5,000.00 |
| Gang Tian | Germantown, TN | Hematology & Oncology | $1,000.00 |
| Russell Gollard | Henderson, NV | Hematology & Oncology | $1,000.00 |
| Salim Contractor | Hudson, NY | Medical Oncology | $1,000.00 |
| Giancarlo Pillot | Bridgeton, MO | Hematology & Oncology | $1,000.00 |
| Sandeep Chunduri | Crystal Lake, IL | Hematology & Oncology | $423.53 |
| Kevin Dawravoo | Warrenville, IL | Hematology & Oncology | $423.53 |
| Shalin Shah | Plainfield, IL | Internal Medicine | $423.53 |
| M Mufaddal Hamadeh | Tinley Park, IL | Hematology & Oncology | $423.53 |
Prescribed Cyclophosphamide?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.